<scp>ASP</scp>8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients with <i><scp>EGFR</scp></i> mutation‐positive non‐small‐cell lung cancer
Koichi Azuma(Kyushu University Hospital), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Akira Inoue(Tohoku University Hospital), Hidetoshi Hayashi(Kindai University), Tomoki Nakagawa(Astellas Pharma (Japan)), Seitaro Asahina(Astellas Pharma (Japan)), Katsuyuki Kiura(Okayama University Hospital), Satoshi Ikeda, Makoto Nishio(Japanese Foundation For Cancer Research), Shunichi Sugawara(Sendai Kousei Hospital), Toyoaki Hida(Saitama International Medical Center), Kentaro Takeda(Center for Global Development), Satoshi Morita(Kyoto University), Yasuo Iwamoto(Hiroshima City Asa Citizens Hospital), Masahiro Fukuoka(National Institute of Standards and Technology), Koji Takeda(NewYork–Presbyterian Hospital), Kanji Komatsu(Astellas Pharma (Japan)), Miyako Satouchi(Memorial Sloan Kettering Cancer Center)
Cited by 35
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k